| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Sp17 |
| Uniprot No | Q15506 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-146aa |
| 氨基酸序列 | MSIPFSNTHYRIPQGFGNLLEGLTREILREQPDNIPAFAAAYFESLLEKREKTNFDPAEWGSKVEDRFYNNHAFEEQEPPEKSDPKQEESQISGKEEETSVTILDSSEEDKEKEEVAAVKIQAAFRGHIAREEAKKMKTNSLQNEE |
| 预测分子量 | 43.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Sp17重组蛋白的3篇代表性文献的简要整理(注：文献信息为模拟示例，实际引用需验证)：
1. **《Recombinant Sp17 protein induces antibody response in ovarian cancer patients》**
- 作者：Smith A, et al.
- 摘要：研究通过大肠杆菌表达系统制备重组Sp17蛋白，发现其在卵巢癌患者血清中能激发特异性抗体反应，提示其作为癌症免疫治疗靶点的潜力。
2. **《Characterization of human sperm protein Sp17: implications for contraceptive vaccine development》**
- 作者：Goyal R, et al.
- 摘要：解析Sp17重组蛋白的免疫原性，证明其在动物模型中可抑制精子运动，为开发基于Sp17的避孕疫苗提供理论基础。
3. **《Sp17 expression in multiple myeloma and its role in tumor progression》**
- 作者：Lee C, et al.
- 摘要：利用重组Sp17蛋白探究其在多发性骨髓瘤中的异常表达，发现Sp17通过调控细胞迁移促进肿瘤转移，为靶向治疗提供依据。
**提示**：实际研究中建议通过PubMed或Google Scholar检索最新文献，并结合具体研究方向筛选。部分经典研究可能涉及Sp17的基因克隆(如Frayne et al., 1998)或结构解析(如Sharma et al., 2002)。
**Background of SP17 Recombinant Protein**
Sperm protein 17 (SP17), initially identified in human spermatozoa, is a highly conserved protein implicated in gamete interactions during fertilization. Structurally, it comprises a heparin-binding domain at the N-terminus and a transmembrane domain at the C-terminus, facilitating its role in cell adhesion and signaling. While SP17 is predominantly expressed in the testis under physiological conditions, aberrant expression has been observed in various cancers, including multiple myeloma, ovarian cancer, and squamous cell carcinomas, suggesting potential involvement in tumor progression and metastasis.
The recombinant SP17 protein is engineered through molecular cloning techniques, often expressed in bacterial (e.g., *E. coli*) or mammalian systems to ensure proper folding and post-translational modifications. Its recombinant form enables detailed studies on molecular mechanisms, antigenicity, and therapeutic applications. SP17 has garnered attention as a cancer-testis antigen (CTA), a class of proteins restricted to germ cells but reactivated in malignancies, making it a candidate for immunotherapy. Preclinical studies explore its use in vaccine development or as a target for antibody-based therapies.
However, SP17’s pathophysiological role remains debated. Some studies propose it promotes cancer cell migration via interactions with extracellular matrix components, while others highlight its immunosuppressive properties. Additionally, its expression variability across cancer types complicates its utility as a universal biomarker. Current research focuses on elucidating SP17’s signaling pathways, structural epitopes for immune recognition, and clinical validation in targeted therapies. Despite challenges, recombinant SP17 continues to serve as a valuable tool for reproductive biology and oncology research.
×
